Ani Pharmaceuticals (ANIP) Change in Receivables (2012 - 2026)

Ani Pharmaceuticals has disclosed Change in Receivables across 15 years of filings, most recently posting $19.1 million for Q2 2026.

• In Q2 2026, Change in Receivables rose 247.42% year-over-year to $19.1 million; the TTM figure through Jun 2026 stood at $48.4 million (up 132.73% YoY), while the FY2025 annual figure was $58.5 million, up 177.56% from the prior year.
• Change in Receivables came in at $19.1 million for Q2 2026 at Ani Pharmaceuticals, up from -$25.5 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $27.9 million in Q4 2025 to a low of -$25.5 million in Q1 2026.
• Average Change in Receivables over 5 years is $5.9 million, with a median of $5.7 million recorded in 2023.
• Year-over-year, Change in Receivables soared 2333.29% in 2022 and sank 1332.55% in 2026.
• Over 5 years, Change in Receivables stood at $25.0 million in 2022, then tumbled by 167.04% to -$16.8 million in 2023, then jumped by 252.2% to $25.5 million in 2024, then rose by 9.18% to $27.9 million in 2025, then sank by 31.52% to $19.1 million in 2026.
• Per Business Quant data, the three most recent Change in Receivables figures were $19.1 million in Q2 2026, -$25.5 million in Q1 2026, and $27.9 million in Q4 2025.